4SC AG
VSC | F
Overview
Corporate Details
- ISIN(s):
- DE000A3E5C40
- LEI:
- 391200QOKN7LGVP0RQ86
- Country:
- Germany
- Address:
- Fraunhoferstr. 22, 82152 Planegg
- Website:
- https://www.4sc.com/
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
4SC focuses on the development of novel small molecule drugs that target key mechanisms of cancer development, such as histone deacetylases (HDAC). Such drugs are intended to provide patients with innovative treatment options that are more tolerable and efficacious than existing therapies and provide a better quality of life. 4SC's current product pipeline includes two programs in clinical development: resminostat and domatinostat. 4SC's goal is to advance its own drug development programs in order to increase the value of the Company as a whole through entering into valuable partnerships with pharmaceutical and biotechnology companies for the further development or commercialization of 4SC drug candidates, and/or the eventual marketing and sales of approved drugs in select territories, such as Europe.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2020-05-08 00:00 |
Quarterly Report
Q1 statement / Q1 financial report 2020
|
English | 489.3 KB | |
| 2020-04-21 07:30 |
Earnings Release
4SC provides Q1 2020 update
|
English | 10.9 KB | |
| 2020-04-17 00:00 |
Annual Report
Annual financial report 2019
|
English | 1.1 MB | |
| 2020-04-17 00:00 |
Annual Report
Annual financial report 2019
|
German | 1.1 MB | |
| 2020-04-16 07:30 |
Regulatory News Service
4SC AG: Conference call to be hosted on 21 April 2020 to present the Q1 report …
|
English | 9.3 KB | |
| 2020-04-15 15:06 |
General Meeting Notice
4SC AG: Bekanntmachung der Einberufung zur Hauptversammlung am 08.05.2020 in Pl…
|
German | 92.2 KB | |
| 2020-04-08 07:30 |
Regulatory News Service
4SC AG: FDA Accepts IND Application for MERKLIN 2 Study
|
English | 14.1 KB | |
| 2020-03-25 07:30 |
Earnings Release
4SC AG provides results for financial year 2019 and outlook
|
English | 13.2 KB | |
| 2020-02-12 07:30 |
Regulatory News Service
4SC to present at the World Congress of Cutaneous Lymphomas in Barcelona, Spain
|
English | 14.3 KB | |
| 2020-01-31 07:30 |
Regulatory News Service
4SC - Resminostat and RESMAIN Study Update
|
English | 16.5 KB | |
| 2020-01-15 07:30 |
Regulatory News Service
4SC AG: First Patient Enrolled in DONIMI Study Evaluating Domatinostat in the N…
|
English | 15.0 KB | |
| 2020-01-09 07:30 |
Regulatory News Service
4SC AG: 3 upcoming conferences
|
English | 8.4 KB | |
| 2020-01-07 07:30 |
Regulatory News Service
4SC AG enters into avelumab supply agreement with Merck KGaA, Darmstadt, German…
|
English | 13.8 KB | |
| 2019-12-19 11:30 |
Declaration of Voting Results & Voting Rights Announcements
|
English | 15.2 KB | |
| 2019-12-19 11:15 |
Report Publication Announcement
|
English | 4.9 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC | |
|
Adocia | France | ADOC |